Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer

Experimental and Molecular Pathology

Volumn 83, Issue 3, 2007, Pages 385-391

  Gallucci, Michele ^a   Vico, Erika ^a   Merola, Roberta ^a   Leonardo, Costantino ^a   Sperduti, Isabella ^a   Felici, Alessandra ^a   Sentinelli, Steno ^a   Cantiani, Ruggero ^a   Orlandi, Giulia ^a   Cianciulli, AnnaMaria ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bladder cancer; Clinical outcome; Genetics; Prognosis

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PROTEIN P16; PROTEIN P53;

ADVERSE OUTCOME; ARTICLE; BLADDER CANCER; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME DELETION; CYSTECTOMY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENETIC PREDISPOSITION; HER2 GENE; HEREDITY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; P16 GENE; P53 GENE; PROGNOSIS; RB1 GENE; TREATMENT OUTCOME;

CHROMOSOME ABERRATIONS; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 36048955430     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2007.08.017     Document Type: Article

References (28)

1. Bangma C., and Jenster G. Bladder carcinogenesis, in search of clues and genes. Eur. Urol. 50 (2006) 205-207
2. Blaveri E., Brewer J.L., Roydasgupta R., Fridlyand J., De Vries S., Koppie T., Pejavar S., Mehta K., Carroll P., Simko J.P., and Waldman F.M. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin. Cancer Res. 11 (2005) 7012-7022
3. Chatterjee S.J., Datar R., Youssefzadeh D., George B., Goebell P.J., Stein J.P., Young L., Shi S.R., Gee C., Groshen S., Skinner D.G., and Cote R.J. Combined effects of p53, p21 and pRB expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22 (2004) 1007-1013
4. Cianciulli A.M., Bovani R., Leonardo F., Antenucci A., Gandolfo G.M., Giannarelli D., Leonardo C., Iori F., and Laurenti C. Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy, histopathology and clinical outcome. Int. J. Clin. Lab. Res. 30 (2000) 5-11
5. Cianciulli A.M., Bovani R., Leonardo C., Iori F., Coletta A.M., Marzano R., Antenucci A., Gandolfo G.M., and Laurenti C. DNA Aberrations in urinary bladder cancer detected by flow cytometry and FISH: prognostic implications. Eur. J. Histochem. 45 (2001) 65-71
6. Cordon-Cardo C. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?. J. Clin. Oncol. 2 (2004) 975-977
7. Cote R.J., and Datar R.H. Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit. Rev. Oncol./Hematol. 46 (2003) S67-S83
8. Denziger S., Mohren K., Knuechel R., Wild P.J., Burger M., Wieland W.F., Hartmann A., and Stoehr R. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum. Pathol. 37 (2006) 143-151
9. Epstein J.I., Amin M.B., Reuter V.R., and Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 22 (1998) 1435-1448
10. Gallucci M., Guadagni F., Marzano R., Leonardo C., Merola R., Sentinelli S., Ruggeri E.M., Cantiani R., Sperduti I., and Cianciulli A.M. p53, p16, RB1, HER-2 genes and 3, 7, 9, 17 chromosomes status in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J. Clin. Pathol. 58 (2005) 367-371
11. Gallucci M., Merola R., Leonardo C., Ruggeri E.M., and Cianciulli A.M. Analysis of HER2 expression in primary urinary bladder carcinoma an corresponding metastases. BJU Int. 96 (2005) 440
12. Greenacre M.J. Theory and Applications of Correspondence Analysis (1984), Academic Press, London
13. Hartmann A., Schlake G., Zaak D., Hungerhuber E., Hofstetter A., Hofstaedter F., and Knuechel R. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 62 (2002) 809-818
14. Karam J.A., Lotan Y., Karakiewicz P.I., Ashfaq R., Sagalowsky A.I., Roehrborn C.G., and Shariat S.F. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 8 (2007) 128-136
15. Jefford C.E., and Irminger-Finger I. Mechanisms of chromosome instability in cancers. Crit. Rev. Oncol./Hematol. 59 (2006) 1-14
16. Lebart L., Morineau A., and Warwick K. Multivariate Descriptive Statistical Analysis (1984), Wiley, New York
17. Merola R., Mottolese M., Orlandi G., Vico E., Sperduti I., Fabi A., Vitelli G., and Cianciulli A.M. Analysis of aneusomy level and HER2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur. J. Cancer 42 (2006) 1501-1506
18. Mitra A.P., Datar R.H., and Cote R.J. Molecular staging of bladder cancer. BJU Int. 96 (2005) 7-12
19. Pycha A., Mian C., Posch B., Haitel A., Mokhtar A.A., El-Baz M., Ghoneim M.A., and Marberger M. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators ?. Urology 53 (1999) 1005-1010
20. Sanchez-Carbayo M., and Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin. Oncol. 34 (2007) 75-84
21. Sauter G., Moch H., Moore D., Carroll P., Kerschmann R., Chew K., Mihatsch M.J., Gudat F., and Waldman F. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53 (1993) 2199-2203
22. Schmitz-Drager B.J., Goebell P.J., Ebert T., and Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. Eur. Urol. 38 (2000) 691-699
23. Shariat S.F., Tokunaga H., Zhou J.H., Kim J.K., Ayala G.E., Benedict W.F., and Lerner S.P. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22 (2004) 1014-1024
24. Shariat S.F., Zlotta A.R., Ashfaq R., Sagalowsky A.I., and Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod. Path. 20 (2007) 445-459
25. Stadler W.M., Steinberg G., Yang X., Hagos F., Turner C., and Olopade O.I. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin. Cancer Res. 7 (2001) 1676-1682
26. Tokunaga H., Shariat S.F., Green A.E., Brown R.M., Zhou J.H., Benedict W.F., and Lerner S.P. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 16-22
27. UICC. TNM Classification of Malignant Tumors. Sixth Edition (2002), Wiley-Liss, New York
28. Wolf H.K., Stober C., Hohenfellner R., and Leissner J. Prognostic value of p53, p21/WAF1, Bcl2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol. 22 (2001) 328-336